AVTR
BEARISH
$11.8
Live
Avantor, Inc. · NYSE
Target $13.04
(+10.5%)
$10.62
52W Range
$23.32
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$8.05B
P/E
N/A
ROE
-1.5%
Profit margin
-1.2%
Debt/Equity
0.69
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
The Advanced Deterministic Scorecard reveals significant financial weakness with a Piotroski F-Score of just 2/9, indicating poor profitability, deteriorating margins, and weak operating performance. Despite a reasonable Debt/Equity ratio and positive operating cash flow proxies, the company is unprofitable on a net basis (negative net margin and ROE), with declining revenue and earnings. Insider selling, a bearish technical trend, and a sharp multi-year price decline further reinforce deterioration in fundamentals. Although the forward P/E of 12.97 appears low, weak execution, shrinking profits, and lack of intrinsic value benchmarks suggest the market is pricing in continued challenges.
Key Strengths
Forward P/E of 12.97 suggests potential undervaluation relative to sector average P/E of 202.93
Operating margin remains healthy at 8.48%, indicating pricing power or cost control at operational level
Debt/Equity ratio of 0.69 is below sector average of 2.31, suggesting conservative capital structure
Gross margin of 33.13% reflects strong underlying product economics
Current ratio of 1.49 indicates short-term liquidity adequacy
Key Risks
Piotroski F-Score of 2/9 signals severe financial distress and high risk of continued underperformance
Negative net profit margin (-1.25%) and negative ROE (-1.48%) indicate systemic profitability issues
Revenue declining YoY by 5.30% and EPS down 15.4% YoY point to deteriorating fundamentals
Insider selling activity in last 6 months reflects lack of confidence from management
Technical trend score of 0/100 and 1Y price drop of 46% suggest strong bearish momentum
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
55
20
25
18
0
AI Verdict
High-risk profile with deteriorating fundamentals and weak financial health
Key drivers: Low Piotroski F-Score (2/9), Negative net profitability, Declining revenue and earnings, Bearish insider and technical signals
Confidence
88%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 12.97 is below historical and sector medians
- Price/Sales of 1.22 is reasonable for healthcare supplies
Watchpoints
- No Graham Number or intrinsic value available
- P/B of 1.44 not supportive given negative ROE
Future
20/100
Ref Growth rates
Positives
- Forward P/E implies some growth expectations
Watchpoints
- Revenue Growth (YoY): -5.30%
- Earnings Growth (YoY): N/A (but down 15.4% on EPS)
- Q/Q EPS growth: -8.3%
Past
25/100
Ref Historical trends
Positives
- Historically beat earnings estimates in earlier years (e.g., +25.9% in 2021)
Watchpoints
- Last 4 quarters missed estimates (0/4 beats)
- 5Y price return: -61.5%
- 1Y price return: -46.0%
Health
18/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.49 supports short-term solvency
- Quick ratio of 0.88, though low, is not critical
Watchpoints
- Piotroski F-Score: 2/9 (Weak)
- ROE: -1.48%
- Net Profit Margin: -1.25%
- Altman Z-Score: None (missing, but financials suggest distress risk)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$11.8
Analyst Target
$13.04
Upside/Downside
+10.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AVTR and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AVTR
Avantor, Inc.
Primary
|
-61.5% | -48.8% | -46.0% | -17.0% | +4.6% | -3.0% |
|
HALO
Halozyme Therapeutics, Inc.
Peer
|
+57.9% | +84.6% | +17.5% | +5.8% | +2.0% | +5.2% |
|
CYTK
Cytokinetics, Incorporated
Peer
|
+170.7% | +87.1% | +81.9% | +8.8% | +4.9% | -0.7% |
|
BIO
Bio-Rad Laboratories, Inc.
Peer
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-40.4% | -45.2% | -50.0% | -23.3% | +11.7% | +2.4% |
AVT
Avantor, Inc.
Primary
5Y
-61.5%
3Y
-48.8%
1Y
-46.0%
6M
-17.0%
1M
+4.6%
1W
-3.0%
HAL
Halozyme Therapeutics, Inc.
Peer
5Y
+57.9%
3Y
+84.6%
1Y
+17.5%
6M
+5.8%
1M
+2.0%
1W
+5.2%
CYT
Cytokinetics, Incorporated
Peer
5Y
+170.7%
3Y
+87.1%
1Y
+81.9%
6M
+8.8%
1M
+4.9%
1W
-0.7%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-49.6%
3Y
-35.1%
1Y
-15.9%
6M
+12.3%
1M
-1.7%
1W
-5.4%
MOH
Molina Healthcare, Inc.
Peer
5Y
-40.4%
3Y
-45.2%
1Y
-50.0%
6M
-23.3%
1M
+11.7%
1W
+2.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
12.97
PEG Ratio
N/A
P/B Ratio
1.44
P/S Ratio
1.22
EV/Revenue
1.77
EV/EBITDA
10.78
Market Cap
$8.05B
Profitability
Profit margins and return metrics
Profit Margin
-1.25%
Operating Margin
8.48%
Gross Margin
33.13%
ROE
-1.48%
ROA
3.43%
Growth
Revenue and earnings growth rates
Revenue Growth
-5.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.69
Moderate
Current Ratio
1.49
Good
Quick Ratio
0.88
Poor
Cash/Share
$0.37
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-11
$N/A
2025-10-29
$0.22
-2.3% surprise
2025-08-01
$0.24
-2.9% surprise
2025-04-25
$0.23
-0.7% surprise
Healthcare Sector Comparison
Comparing AVTR against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-1.48%
This Stock
vs
-88.14%
Sector Avg
-98.3%
(Below Avg)
Profit Margin
-1.25%
This Stock
vs
-16.28%
Sector Avg
-92.3%
(Weaker)
Debt to Equity
0.69
This Stock
vs
2.66
Sector Avg
-74.0%
(Less Debt)
Revenue Growth
-5.3%
This Stock
vs
124.04%
Sector Avg
-104.3%
(Slower)
Current Ratio
1.49
This Stock
vs
4.47
Sector Avg
-66.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AVTR
Avantor, Inc.
|
BEARISH | $8.05B | - | -1.5% | -1.2% | $11.8 | |
|
HALO
Halozyme Therapeutics, Inc.
|
NEUTRAL | $8.03B | 26.49 | 153.6% | 22.7% | $67.82 | Compare |
|
CYTK
Cytokinetics, Incorporated
|
NEUTRAL | $8.06B | - | -% | -% | $65.48 | Compare |
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | Compare |
|
MOH
Molina Healthcare, Inc.
|
BEARISH | $7.87B | 16.83 | 11.0% | 1.1% | $151.0 | Compare |
AVTR
Avantor, Inc.
BEARISH
Mkt Cap
$8.0B
P/E
-
ROE
-1.5%
Price
$11.8
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | DINGEMANS SIMON | Director | Stock Award | 6,225 | - |
| 2025-12-05 | MEHRA SANJEEV K | Director | Stock Award | 8,106 | - |
| 2025-12-05 | MEHRA SANJEEV K | Director | Purchase | 350,000 | $3,881,500 |
| 2025-11-17 | LIGNER EMMANUEL | Chief Executive Officer | Purchase | 87,500 | $993,125 |
| 2025-11-10 | BLENN MARY | Chief Operating Officer | Stock Award | 17,391 | - |
| 2025-10-30 | SUMME GREGORY L | Director | Purchase | 100,000 | $1,125,000 |
| 2025-10-03 | LUCIER GREGORY T | Director | Stock Award | 8,736 | - |
| 2025-08-21 | SUMME GREGORY L | Director | Purchase | 100,000 | $1,256,000 |
| 2025-08-18 | LIGNER EMMANUEL | Chief Executive Officer | Stock Award | 195,924 | - |
| 2025-08-08 | COUTURIER CHRISTOPHE | Officer | Stock Award | 65,217 | - |
| 2025-08-05 | ECK STEVEN W. | Officer | Sale | 3,476 | $39,592 |
DINGEMANS SIMON
Director
2026-01-02
6,225 shares
MEHRA SANJEEV K
Director
2025-12-05
8,106 shares
MEHRA SANJEEV K
Director
2025-12-05
350,000 shares
·
$3,881,500
LIGNER EMMANUEL
Chief Executive Officer
2025-11-17
87,500 shares
·
$993,125
BLENN MARY
Chief Operating Officer
2025-11-10
17,391 shares
SUMME GREGORY L
Director
2025-10-30
100,000 shares
·
$1,125,000
LUCIER GREGORY T
Director
2025-10-03
8,736 shares
SUMME GREGORY L
Director
2025-08-21
100,000 shares
·
$1,256,000
LIGNER EMMANUEL
Chief Executive Officer
2025-08-18
195,924 shares
COUTURIER CHRISTOPHE
Officer
2025-08-08
65,217 shares
ECK STEVEN W.
Officer
2025-08-05
3,476 shares
·
$39,592
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
14 analysts
TD Cowen
2026-01-07
Hold
Hold
Evercore ISI Group
2026-01-05
Outperform
In-Line
Jefferies
2025-12-17
Hold
Underperform
Evercore ISI Group
2025-10-30
Outperform
Outperform
Barclays
2025-10-30
Overweight
Equal-Weight
JP Morgan
2025-10-30
Overweight
Neutral
Baird
2025-10-24
Outperform
Outperform
Raymond James
2025-10-16
Outperform
Outperform
Barclays
2025-10-02
Overweight
Overweight
Stifel
2025-08-04
Hold
Hold
Past News Coverage
Recent headlines mentioning AVTR from our newsroom.
Newest → oldest
No matching news yet.